Trial reportThe Journal of pediatrics2020
Neonatal Abstinence Syndrome Severity Index Predicts 18-Month Neurodevelopmental Outcome in Neonates Randomized to Morphine or Methadone.
Trial report in The Journal of pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Opioid treatment for opioid withdrawal in newborn infants.The Cochrane database of systematic reviews · 2021Pooled it
- Association between NNNS-II profiles and pharmacological treatment in infants with prenatal opioid exposure.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- Delineating the effects of prenatal oxycodone exposure and melatonin treatment on placental and fetal outcomes in pregnant rats.bioRxiv : the preprint server for biology · 2026Article
- Association between NNNS-II Profiles and Pharmacological Treatment in Infants with Prenatal Opioid Exposure.Research square · 2025Article
- Neonatal Neurobehavior Predicts Neonatal Opioid Withdrawal Syndrome Severity Prior to Treatment Interventions.The Journal of pediatrics · 2025Article
- Neurobehavioral Profiles in Opioid-Exposed and Unexposed Neonates.The Journal of pediatrics · 2025Observational
- Evidence for neurobehavioral risk phenotypes at birth.Pediatric research · 2025Review
- Early developmental trajectory of children with prenatal alcohol and opioid exposure.Pediatric research · 2024Article
- The Neonatal Withdrawal Assessment Tool (NWAT): pilot inter-rater reliability and content validity.Journal of perinatology : official journal of the California Perinatal Association · 2023Article
- Opioid and Methadone Use for Infants With Surgically Treated Necrotizing Enterocolitis.JAMA network open · 2023Article
- Analysis of Neonatal Neurobehavior and Developmental Outcomes Among Preterm Infants.JAMA network open · 2022Article
- The placenta as a target of opioid drugs†.Biology of reproduction · 2022Review
- Effects of Pharmacologic Treatment for Neonatal Abstinence Syndrome on DNA Methylation and Neurobehavior: A Prospective Cohort Study.The Journal of pediatrics · 2022Article
- Disarray in the perinatal management of neonatal abstinence syndrome.Pediatric research · 2022Article
- The immediate and long-term effects of prenatal opioid exposure.Frontiers in pediatrics · 2022Review
- Transcutaneous Auricular Neurostimulation (tAN): A Novel Adjuvant Treatment in Neonatal Opioid Withdrawal Syndrome.Frontiers in human neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo develop an index to determine which opioid-exposed neonates have the most severe neonatal abstinence syndrome (NAS). STUDY
designFull-term neonates with NAS (n = 116) from mothers maintained on methadone or buprenorphine were enrolled from 8 sites into a randomized clinical trial of morphine vs methadone. Ninety-nine (85%) were evaluated at hospital discharge using the NICU Network Neurobehavioral Scale (NNNS). At 18 months, 83 of 99 (83.8%) were evaluated with the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III), and 77 of 99 (77.7%) were evaluated with the Child Behavior Checklist (CBCL).
resultsCluster analysis was used to define high (n = 21) and low (n = 77) NAS severity. Compared with infants in the low NAS severity cluster, infants in the high NAS severity cluster had a longer length of stay (P < .001), longer length of stay due to NAS (P < .001), longer duration of treatment due to NAS (P < .001), and higher total dose of the study drug (P < .001) and were more likely to have received phenobarbital (P < .001), to have been treated with morphine (P = .020), and to have an atypical NNNS profile (P = .005). The 2 groups did not differ in terms of maximum Finnegan score. At 18 months, in unadjusted analyses, compared with the high-severity cluster, the low-severity cluster had higher scores on the Bayley-III Cognitive (P = .013), Language (P < .001), and Motor (P = .041) composites and less total behavior problems on the CBCL (P = .028). In adjusted analyses, the difference in the Bayley-III Language composite remained (P = .013).
conclusionsPresumptive measures of NAS severity can be aggregated to develop an index that predicts developmental outcomes at age 18 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.